Original article by Pia Akerman
The Australian – Page: 21 : 16-Oct-14

John Shine, chair of Australian-listed biotechnology group CSL, addressed its AGM on 15 October 2014. He said the company was in talks with the World Health Organisation on a potential push to create new drugs for the fight against the Ebola virus. However there are no immediate plans for the development of a vaccine, which is at least a year away according to CEO Paul Perreault. Meanwhile CSL has announced a $A950m stock repurchasing scheme, following six previous such moves that were worth $A3.3bn combined

CORPORATES
CSL LIMITED – ASX CSL, WORLD HEALTH ORGANIZATION